Literature DB >> 16023877

The molecular basis of idiopathic short stature.

Ron G Rosenfeld1.   

Abstract

Forty years ago, when growth hormone (GH) first became available for use, the molecular basis for growth hormone deficiency (GHD) was entirely unknown. Despite continued difficulties with the biochemical diagnosis of GHD, we now accept the existence of underlying genetic abnormalities as the basis for disorders involving GH secretion. Similar challenges are encountered when one considers the causes of non-GHD short stature, namely idiopathic short stature (ISS). Categorization of the causes for ISS by insulin-like growth factor I (IGF-I) concentrations provides a basis for speculation about the potential for IGF-I gene polymorphisms or binding protein abnormalities influencing the development of ISS-related growth failure.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16023877     DOI: 10.1016/j.ghir.2005.06.014

Source DB:  PubMed          Journal:  Growth Horm IGF Res        ISSN: 1096-6374            Impact factor:   2.372


  11 in total

1.  Common VDR polymorphisms and idiopathic short stature in children from northern Greece.

Authors:  E Emmanouilidou; A Galli-Tsinopoulou; I Kyrgios; E Gbandi; A Goulas
Journal:  Hippokratia       Date:  2015 Jan-Mar       Impact factor: 0.471

Review 2.  Short and tall stature: a new paradigm emerges.

Authors:  Jeffrey Baron; Lars Sävendahl; Francesco De Luca; Andrew Dauber; Moshe Phillip; Jan M Wit; Ola Nilsson
Journal:  Nat Rev Endocrinol       Date:  2015-10-06       Impact factor: 43.330

3.  Study of the leptin levels and its gene polymorphisms in patients with idiopathic short stature and growth hormone deficiency.

Authors:  Pen-Hua Su; Shun-Fa Yang; Ju-Shan Yu; Suh-Jen Chen; Jia-Yuh Chen
Journal:  Endocrine       Date:  2012-02-19       Impact factor: 3.633

4.  Growth hormone/insulin-like growth factor-1 axis as related to body mass index in patients with idiopathic short stature.

Authors:  Pinar Cengiz; Firdevs Bas; Fatmahan Atalar; Ahmet Ucar; Feyza Darendeliler; Gökce Akan; Tuğba Tarhan; Rüveyde Bundak
Journal:  J Clin Res Pediatr Endocrinol       Date:  2013-02-19

Review 5.  Emerging options in growth hormone therapy: an update.

Authors:  Stephen F Kemp; J Paul Frindik
Journal:  Drug Des Devel Ther       Date:  2011-08-30       Impact factor: 4.162

6.  Toward gene therapy of Laron syndrome.

Authors:  Haim Werner
Journal:  Gene Ther       Date:  2022-03-14       Impact factor: 4.184

7.  The IGF1 P2 promoter is an epigenetic QTL for circulating IGF1 and human growth.

Authors:  Meriem Ouni; Yasemin Gunes; Marie-Pierre Belot; Anne-Laure Castell; Delphine Fradin; Pierre Bougnères
Journal:  Clin Epigenetics       Date:  2015-03-13       Impact factor: 6.551

Review 8.  Laron Syndrome Research Paves the Way for New Insights in Oncological Investigation.

Authors:  Haim Werner; Rive Sarfstein; Karthik Nagaraj; Zvi Laron
Journal:  Cells       Date:  2020-11-09       Impact factor: 6.600

9.  A proteomic approach identified growth hormone-dependent nutrition markers in children with idiopathic short stature.

Authors:  Gunnel Hellgren; Björn Andersson; Andreas Fm Nierop; Jovanna Dahlgren; Ze'ev Hochberg; Kerstin Albertsson-Wikland
Journal:  Proteome Sci       Date:  2008-12-11       Impact factor: 2.480

10.  Replication and discovery of musculoskeletal QTLs in LG/J and SM/J advanced intercross lines.

Authors:  Ana I Hernandez Cordero; Peter Carbonetto; Gioia Riboni Verri; Jennifer S Gregory; David J Vandenbergh; Joseph P Gyekis; David A Blizard; Arimantas Lionikas
Journal:  Physiol Rep       Date:  2018-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.